Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 9,500 shares at an average price of $568.81 for ≈$5.40M, leaving her with 40,513 shares and representing a 19% reduction in her ownership; the sale was disclosed in an SEC filing.
• The company reported quarterly EPS of $7.70 (vs. $6.78 expected) and revenue of $790.2M (up 7.4% YoY but slightly below estimates), and analysts have raised price targets with a consensus rating of Moderate Buy and a $601.50 consensus target.
• Shares traded around $569 (up ~0.4%) with a market cap of about $24.94B, a PE ratio of 20.4, and a 12‑month range of $272.12–$607.89.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction on Monday, April 27th. The shares were sold at an average price of $568.81, for a total transaction of $5,403,695.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $23,044,199.53. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Trading Up 0.4%

Shares of UTHR stock traded up $2.12 during trading hours on Tuesday, hitting $569.11. The company's stock had a trading volume of 342,769 shares, compared to its average volume of 486,570. The company has a 50 day moving average of $538.38 and a 200 day moving average of $495.47. The stock has a market cap of $24.94 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 1.61 and a beta of 0.75. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $607.89.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm earned $6.19 EPS. As a group, analysts anticipate that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

UTHR has been the topic of several recent research reports. HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. Raymond James Financial began coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an "outperform" rating and a $700.00 target price for the company. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 31st. Finally, UBS Group boosted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $601.50.

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management lifted its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock worth $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC lifted its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth about $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.